{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T18:39:01Z","timestamp":1785091141977,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.mayocp.2019.03.028","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T17:01:01Z","timestamp":1565370061000},"page":"1670-1680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients"],"prefix":"10.1016","volume":"94","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5329-8125","authenticated-orcid":false,"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Granowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocp.2019.03.028_bib1","first-page":"e67","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association [published correction appears in Circulation. 2018;137(12):e493]","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.028_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.028_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/heartjnl-2012-302689","article-title":"Mortality risk of triglyceride levels in patients with coronary artery disease","volume":"99","author":"Kasai","year":"2013","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.028_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.028_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease [published correction appears in J Am Coll Cardiol. 2019;73(8):987-988]","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.028_bib7","doi-asserted-by":"crossref","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.mayocp.2019.03.028_bib8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.028_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","article-title":"Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease","volume":"118","author":"Budoff","year":"2016","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.028_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.028_bib11","first-page":"22","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease [published correction appears in N Engl J Med. 2015;372(7):690]","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2019.03.028_bib12","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2015.08.866","article-title":"Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis: the Multi-Ethnic BioImage Study","volume":"66","author":"Natarajan","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7537","key":"10.1016\/j.mayocp.2019.03.028_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"issue":"9726","key":"10.1016\/j.mayocp.2019.03.028_bib14","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2019.03.028_bib15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2019.03.028_bib16","first-page":"1134","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease [published correction appears in N Engl J Med. 2016;374(19):1898]","volume":"374","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7307","key":"10.1016\/j.mayocp.2019.03.028_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.028_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng.784","article-title":"Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease","volume":"43","author":"Schunkert","year":"2011","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.028_bib19","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.028_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"issue":"24","key":"10.1016\/j.mayocp.2019.03.028_bib21","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.mayocp.2019.03.028_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.028_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1373\/clinchem.2013.219881","article-title":"Low nonfasting triglycerides and reduced all-cause mortality: a\u00a0mendelian randomization study","volume":"60","author":"Thomsen","year":"2014","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.028_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.mayocp.2019.03.028_bib25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.mayocp.2019.03.028_bib26","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins [published correction appears in J Am Coll Cardiol. 2015;66(3):334]","volume":"65","author":"Schwartz","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.028_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"issue":"15","key":"10.1016\/j.mayocp.2019.03.028_bib28","doi-asserted-by":"crossref","first-page":"e008740","DOI":"10.1161\/JAHA.118.008740","article-title":"High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk","volume":"7","author":"Toth","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.mayocp.2019.03.028_bib29","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/jc.2018-00470","article-title":"Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol","volume":"103","author":"Nichols","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.mayocp.2019.03.028_bib30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjcard.2018.06.029","article-title":"Comparison of medical care utilization and costs among patients with statin-controlled low-density lipoprotein cholesterol with versus without hypertriglyceridemia","volume":"122","author":"Nichols","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mayocp.2019.03.028_bib31","series-title":"Reducing bias in a propensity score matched-pair sample using greedy matching techniques","author":"Parsons","year":"2001"},{"issue":"25,\u00a0part B","key":"10.1016\/j.mayocp.2019.03.028_bib32","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2019.03.028_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2017.9991","article-title":"Multidimensional evidence generation and FDA regulatory decision making: defining and using \"real-world\" data","volume":"318","author":"Jarow","year":"2017","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.mayocp.2019.03.028_bib34","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.028_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.amjcard.2010.09.010","article-title":"Patient characteristics and medical care costs associated with hypertriglyceridemia","volume":"107","author":"Nichols","year":"2011","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.028_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2016.10.029","article-title":"Effect of combination cholesterol-lowering therapy and triglyceride-lowering therapy on medical costs in patients with type 2 diabetes mellitus","volume":"119","author":"Nichols","year":"2017","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.028_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2019.03.028_bib38","unstructured":"American Diabetes Association. American Diabetes Association issues critical updates to the 2019 standards of medical care in diabetes. Website. http:\/\/www.diabetes.org\/newsroom\/press-releases\/2019\/ada-issues-critical-updates-to-2019-standards-of-care.html. Published March 27, 2019. Accessed June 6, 2019."},{"issue":"8","key":"10.1016\/j.mayocp.2019.03.028_bib39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making","volume":"20","author":"Berger","year":"2017","journal-title":"Value Health"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:31:10Z","timestamp":1758418270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619303829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0025619619303829"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.028","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}